by | Nov 5, 2021 | Dodhiawala, Paarth, Lim, Kian-Huat
— Technology Description
Researchers in Kian-Huat Lim’s lab at Washington University have developed a therapeutic strategy to target TPL2 in RAS-mutated cancers, which should work synergistically with chemotherapy and radiation. As TPL2 (MAP3K8) is necessary for upstream activation of both MAP…
by | Oct 27, 2021 | Djuranovic, Sergej, Erath, Jessey Lee, Pavlovic Djuranovic, Slavica
— Technology Description
Researchers in Sergei Djuranovic’s lab at Washington University have developed polybasic peptides and polymers to block Plasmodium falciparum adhesion as a treatment for malaria. These therapeutics reduce parasite infection of human cells, making this a promising alter…
by | Sep 29, 2021 | Ellebedy, Ali
— Disease indication – SARS-CoV-2 infection (COVID-19)
Drug format
Drug class – Best-in-class
Research stage and Preliminary data – The inventors have developed and characterized these antibodies, creating a chimeric version with a human IgG backbone for SARS2-38. The antibodies have …
by | Sep 9, 2021 | Choi, Kyunghee, Kabir, Ashraf Ul, Krchma, Karen
— Technology Description
Researchers in Kyunghee Choi’s lab at Washington University in St. Louis have identified a novel target, Myct1, that modulates tumor angiogenesis and anti-tumor immune response. Myct1 inhibition with siRNA blocks angiogenesis and promotes infiltration of cytotoxic T ly…
by | Sep 6, 2021 | Azab, Abdel Kareem, Azab, Feda, de la Puente Garcia, Maria del Pilar
— Background
External Beam Radiotherapy (EBR) is commonly used after surgical removal of a tumor (in e.g. a breast-conserving surgery) to control or kill malignant cells. The lack of selectivity due to irradiation of whole or partial organs from outside the body, however, is potentially damaging to t…